SA520411067B1 - تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة - Google Patents

تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة

Info

Publication number
SA520411067B1
SA520411067B1 SA520411067A SA520411067A SA520411067B1 SA 520411067 B1 SA520411067 B1 SA 520411067B1 SA 520411067 A SA520411067 A SA 520411067A SA 520411067 A SA520411067 A SA 520411067A SA 520411067 B1 SA520411067 B1 SA 520411067B1
Authority
SA
Saudi Arabia
Prior art keywords
betahistine
dissolved
hours
weight
pulsatile
Prior art date
Application number
SA520411067A
Other languages
English (en)
Inventor
هيمانشوكومار داشاراثلال باتيل
سونيل شانتاون بورود
فينود بوروشوتام دوب
فينكاتارامانا نيدو
Original Assignee
انتاس فارماسوتيكالز ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59829185&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA520411067(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by انتاس فارماسوتيكالز ليمتد filed Critical انتاس فارماسوتيكالز ليمتد
Publication of SA520411067B1 publication Critical patent/SA520411067B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صلبة فموية ممتدة الإطلاق oral solid prolonged-release composition لمدة 24 ساعة غير نابضة تشمل كمية من البيتاهستين betahistine، أو ملح مقبول صيدلانياً pharmaceutically acceptable salt منه، يُكافئ 48 مجم من داي هيدروكلوريد بيتاهستين betahistine dihydrochloride، معاً مع واحد أو أكثر من السواغات excipients أو المواد الحاملة المقبولة صيدلانياً pharmaceutically acceptable carriers، حيث تظهر التركيبة نمط انحلال طبقاً له: تتم إذابة ما يصل إلى 30٪ بالوزن بيتاهستين خلال ساعة واحدة؛ تتم إذابة من 35٪ إلى 45٪ بالوزن بيتاهستين خلال ساعتين؛ تتم إذابة من 46٪ إلى 60٪ بالوزن بيتاهستين خلال 4 ساعات؛ تتم إذابة من 61٪ إلى 80٪ بالوزن بيتاهستين خلال 8 ساعات؛ تتم إذابة 81٪ إلى 97٪ بالوزن بيتاهستين خلال 16 ساعة؛ وتتم إذابة من 98٪ إلى 100٪ بالوزن بيتاهستين خلال 24 ساعة. ويتعلق أيضاً باستخدامها في علاج، تحديداً في معالجة مرض أو حالة دهليزية vestibular condition، بتحديد أكثر في معالجة مرض مينيير Ménière's disease. شكل1
SA520411067A 2017-07-20 2020-01-16 تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة SA520411067B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721025857 2017-07-20
PCT/IB2018/055233 WO2019016668A1 (en) 2017-07-20 2018-07-16 NON-PULSATILE EXTENDED RELEASE BETAHISTINE ORAL SOLID COMPOSITIONS

Publications (1)

Publication Number Publication Date
SA520411067B1 true SA520411067B1 (ar) 2022-09-28

Family

ID=59829185

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411067A SA520411067B1 (ar) 2017-07-20 2020-01-16 تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة

Country Status (22)

Country Link
US (1) US11433058B2 (ar)
EP (2) EP3431078B1 (ar)
JP (1) JP7084950B2 (ar)
CN (1) CN110891551A (ar)
AR (1) AR112281A1 (ar)
AU (1) AU2018302771B2 (ar)
BR (1) BR112020000977A2 (ar)
CA (1) CA3069282A1 (ar)
CL (1) CL2020000124A1 (ar)
CO (1) CO2020001742A2 (ar)
DK (1) DK3431078T3 (ar)
ES (1) ES2862209T3 (ar)
HR (1) HRP20210570T1 (ar)
LT (1) LT3431078T (ar)
MX (1) MX2020000702A (ar)
PH (1) PH12020500001A1 (ar)
PL (1) PL3431078T3 (ar)
PT (1) PT3431078T (ar)
SA (1) SA520411067B1 (ar)
UY (1) UY37798A (ar)
WO (1) WO2019016668A1 (ar)
ZA (1) ZA202000030B (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115266955B (zh) * 2021-04-29 2024-10-01 景忠山国药（唐山）有限公司 基于一测多评法的耳聋胶囊中成分含量的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1309591B1 (it) * 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
EP1406630A1 (en) * 2001-07-06 2004-04-14 Endo Pharmaceuticals Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
ATE395048T1 (de) * 2003-07-04 2008-05-15 Formenti Farmaceutici Spa Betahistinezubereitungen mit kontrollierter freisetzung
WO2012131722A1 (en) * 2011-03-30 2012-10-04 Sun Pharma Advanced Research Company Ltd. Controlled release composition of betahistine
DE102012105528A1 (de) 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
WO2014174073A1 (en) * 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Also Published As

Publication number Publication date
PT3431078T (pt) 2021-04-21
CN110891551A (zh) 2020-03-17
JP7084950B2 (ja) 2022-06-15
US20210161871A1 (en) 2021-06-03
WO2019016668A1 (en) 2019-01-24
LT3431078T (lt) 2021-05-10
ZA202000030B (en) 2021-08-25
CA3069282A1 (en) 2019-01-24
AU2018302771A1 (en) 2020-01-16
AR112281A1 (es) 2019-10-09
CL2020000124A1 (es) 2020-09-21
EP3654954A4 (en) 2021-06-16
EP3431078B1 (en) 2021-01-20
DK3431078T3 (da) 2021-04-19
US11433058B2 (en) 2022-09-06
ES2862209T3 (es) 2021-10-07
AU2018302771B2 (en) 2022-05-12
RU2020101925A (ru) 2021-08-20
JP2020528045A (ja) 2020-09-17
CO2020001742A2 (es) 2020-02-28
PH12020500001A1 (en) 2020-09-14
MX2020000702A (es) 2020-10-14
EP3654954A1 (en) 2020-05-27
UY37798A (es) 2019-01-02
RU2020101925A3 (ar) 2021-08-27
HRP20210570T1 (hr) 2021-09-03
BR112020000977A2 (pt) 2020-07-14
EP3431078A1 (en) 2019-01-23
PL3431078T3 (pl) 2021-07-12

Similar Documents

Publication Publication Date Title
ME02414B (me) Tretman kronove bolesti lakvinimodom
MX2021004431A (es) Procesos novedosos.
MX2019012884A (es) Terapia de combinacion.
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
MX2021002321A (es) Nuevos metodos.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
MX2021002322A (es) Nuevos metodos.
ATE536172T1 (de) Ezetimibzusammensetzungen
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
SA520411067B1 (ar) تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة